Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months

Apogee Therapeutics, Inc.

APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.
Near-complete pSTAT6 inhibition and sustained TARC suppression observed up to 9 months after a single dose.
No serious adverse events; treatment-emergent AEs were mild-to-moderate and unrelated to study drug.
Phase 2 proof-of-concept data in moderate-to-severe AD expected in 2H 2025.
Company plans R&D Day on December 2, 2024 to update on APG777 and pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.